Enhancement of CAR-T cell-targeted immune responses against solid tumors: role of lowered CARs affinity and addition of PD-1 chimeric antigen complexes

Cancers rising prevalence demands novel treatments. Chimeric Antigen Receptor T-cell (CAR-T) therapy emerges as a transformative option. Conventional cancer treatments of-ten lack efficacy and carry severe side effects. This study focuses on enhancing CAR-T therapy against solid tumors. Strategies include lowering CAR affinity for antigens and in-tegrating PD-1&CD-28 chimeric antigen complexes. While CAR-T therapy excels against hematological malignancies, challenges remain, such as immune checkpoint upregulation and potential toxicity. The research aims to optimize CAR-T therapys efficacy through innovative modifications. Alternative strategies like multi-targeted CARs and combina-tions with immune checkpoint inhibitors are explored. Overall, this study advances can-cer therapy by addressing CAR-T therapys limitations and proposing complementary strategies for improved personalized treatments.